Generation of a stable packaging cell line producing high-titer PPT-deleted integration-deficient lentiviral vectors

Molecular Therapy Methods and Clinical Development

Volumn 2, Issue , 2015, Pages 15025-

  Hu, Peirong ^a   Li, Yedda ^b   Sands, Mark S ^b   McCown, Thomas ^a   Kafri, Tal ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENVELOPE PROTEIN; INTEGRASE; INTEGRATION DEFECTIVE LENTIVIRAL VECTOR; LENTIVIRUS VECTOR; TETRACYCLINE; UNCLASSIFIED DRUG; VIRUS DNA; D64E INTEGRASE; GAG PROTEIN; GREEN FLUORESCENT PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE; POL PROTEIN; POLYPURINE TRACT DELETED INTEGRATION DEFICIENT LENTIVIRAL VECTOR; REV PROTEIN; TRANSACTIVATOR PROTEIN; VESICULOVIRUS G ENVELOPE PROTEIN; VIRUS ENVELOPE PROTEIN; VPU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CLONE; CELL LINE; CELL MUTANT; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; NONHUMAN; PACKAGING; PRIORITY JOURNAL; RAT; STABLE TRANSFECTION; VIRAL GENE DELIVERY SYSTEM; VIRUS CONCENTRATION; VIRUS TITRATION; VIRUS VECTOR PACKAGING CELL LINE; ANIMAL CELL; CENTRAL NERVOUS TISSUE; COMPARATIVE STUDY; CYTOMEGALOVIRUS; DNA INTEGRATION; DNA PACKAGING; EMBRYO; GENE CASSETTE; GENETIC TRANSDUCTION; HEK293 CELL LINE; PROMOTER REGION; PVG3 CELL LINE; REPORTER GENE; VESICULOVIRUS;

EID: 84966588701     PISSN: None     EISSN: 23290501     Source Type: Journal    
DOI: 10.1038/mtm.2015.25     Document Type: Article

References (69)

1. 1 Aiuti, A, Biasco, L, Scaramuzza, S, Ferrua, F, Cicalese, MP, Baricordi, C, et al. Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. Science, 341, 2013, 1233151.
2. 2 Biffi, A, Montini, E, Lorioli, L, Cesani, M, Fumagalli, F, Plati, T, et al. Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science, 341, 2013, 1233158.
3. 3 Cartier, N, Hacein-Bey-Abina, S, Bartholomae, CC, Veres, G, Schmidt, M, Kutschera, I, et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 326 (2009), 818–823.
4. 4 Cavazzana-Calvo, M, Payen, E, Negre, O, Wang, G, Hehir, K, Fusil, F, et al. Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature 467 (2010), 318–322.
5. 5 Beard, BC, Dickerson, D, Beebe, K, Gooch, C, Fletcher, J, Okbinoglu, T, et al. Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. Mol Ther 15 (2007), 1356–1365.
6. 6 Cesana, D, Sgualdino, J, Rudilosso, L, Merella, S, Naldini, L, Montini, E, Whole transcriptome characterization of aberrant splicing events induced by lentiviral vector integrations. J Clin Invest 122 (2012), 1667–1676.
7. 7 Hargrove, PW, Kepes, S, Hanawa, H, Obenauer, JC, Pei, D, Cheng, C, et al. Globin lentiviral vector insertions can perturb the expression of endogenous genes in beta-thalassemic hematopoietic cells. Mol Ther 16 (2008), 525–533.
8. 8 Montini, E, Cesana, D, Schmidt, M, Sanvito, F, Ponzoni, M, Bartholomae, C, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol 24 (2006), 687–696.
9. 9 Zhao, Y, Keating, K, Thorpe, R, Comparison of toxicogenomic profiles of two murine strains treated with HIV-1-based vectors for gene therapy. Toxicol Appl Pharmacol 225 (2007), 189–197.
10. 10 Zhou, S, Ma, Z, Lu, T, Janke, L, Gray, JT, Sorrentino, BP, Mouse transplant models for evaluating the oncogenic risk of a self-inactivating XSCID lentiviral vector. PLoS One, 8, 2013, e62333.
11. 11 Hacein-Bey-Abina, S, Garrigue, A, Wang, GP, Soulier, J, Lim, A, Morillon, E, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest 118 (2008), 3132–3142.
12. 12 Howe, SJ, Mansour, MR, Schwarzwaelder, K, Bartholomae, C, Hubank, M, Kempski, H, et al. Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients. J Clin Invest 118 (2008), 3143–3150.
13. 13 Stein, S, Ott, MG, Schultze-Strasser, S, Jauch, A, Burwinkel, B, Kinner, A, et al. Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease. Nat Med 16 (2010), 198–204.
14. 14 Apolonia, L, Waddington, SN, Fernandes, C, Ward, NJ, Bouma, G, Blundell, MP, et al. Stable gene transfer to muscle using non-integrating lentiviral vectors. Mol Ther 15 (2007), 1947–1954.
15. 15 Banasik, MB, McCray, PB Jr, Integrase-defective lentiviral vectors: progress and applications. Gene Ther 17 (2010), 150–157.
16. 16 Bayer, M, Kantor, B, Cockrell, A, Ma, H, Zeithaml, B, Li, X, et al. A large U3 deletion causes increased in vivo expression from a nonintegrating lentiviral vector. Mol Ther 16 (2008), 1968–1976.
17. 17 Engelman, A, Bushman, FD, Craigie, R, Identification of discrete functional domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J 12 (1993), 3269–3275.
18. 18 Kantor, B, Ma, H, Webster-Cyriaque, J, Monahan, PE, Kafri, T, Epigenetic activation of unintegrated HIV-1 genomes by gut-associated short chain fatty acids and its implications for HIV infection. Proc Natl Acad Sci USA 106 (2009), 18786–18791.
19. 19 Petit, C, Schwartz, O, Mammano, F, The karyophilic properties of human immunodeficiency virus type 1 integrase are not required for nuclear import of proviral DNA. J Virol 74 (2000), 7119–7126.
20. 20 Philippe, S, Sarkis, C, Barkats, M, Mammeri, H, Ladroue, C, Petit, C, et al. Lentiviral vectors with a defective integrase allow efficient and sustained transgene expression in vitro and in vivo. Proc Natl Acad Sci USA 103 (2006), 17684–17689.
21. 21 Wanisch, K, Yáñez-Muñoz, RJ, Integration-deficient lentiviral vectors: a slow coming of age. Mol Ther 17 (2009), 1316–1332.
22. 22 Cornu, TI, Cathomen, T, Targeted genome modifications using integrase-deficient lentiviral vectors. Mol Ther 15 (2007), 2107–2113.
23. 23 Ellis, S, Fong-Wong, L, Iqball, S, Thoree, V, Mitrophanous, KA, Binley, K, Assessment of Integration-defective HIV-1 and EIAV Vectors In Vitro and In Vivo. Mol Ther Nucleic Acids, 1, 2012, e60.
24. 24 Kantor, B, Bayer, M, Ma, H, Samulski, J, Li, C, McCown, T, et al. Notable reduction in illegitimate integration mediated by a PPT-deleted, nonintegrating lentiviral vector. Mol Ther 19 (2011), 547–556.
25. 25 Tareen, SU, Kelley-Clarke, B, Nicolai, CJ, Cassiano, LA, Nelson, LT, Slough, MM, et al. Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells. Mol Ther 22 (2014), 575–587.
26. 26 Chick, HE, Nowrouzi, A, Fronza, R, McDonald, RA, Kane, NM, Alba, R, et al. Integrase-deficient lentiviral vectors mediate efficient gene transfer to human vascular smooth muscle cells with minimal genotoxic risk. Hum Gene Ther 23 (2012), 1247–1257.
27. 27 Loewen, N, Leske, DA, Chen, Y, Teo, WL, Saenz, DT, Peretz, M, et al. Comparison of wild-type and class I integrase mutant-FIV vectors in retina demonstrates sustained expression of integrated transgenes in retinal pigment epithelium. J Gene Med 5 (2003), 1009–1017.
28. 28 Michelini, Z, Negri, DR, Baroncelli, S, Spada, M, Leone, P, Bona, R, et al. Development and use of SIV-based Integrase defective lentiviral vector for immunization. Vaccine 27 (2009), 4622–4629.
29. 29 Nightingale, SJ, Hollis, RP, Pepper, KA, Petersen, D, Yu, XJ, Yang, C, et al. Transient gene expression by nonintegrating lentiviral vectors. Mol Ther 13 (2006), 1121–1132.
30. 30 Pelascini, LP, Janssen, JM, Gonçalves, MA, Histone deacetylase inhibition activates transgene expression from integration-defective lentiviral vectors in dividing and non-dividing cells. Hum Gene Ther 24 (2013), 78–96.
31. 31 Peluffo, H, Foster, E, Ahmed, SG, Lago, N, Hutson, TH, Moon, L, et al. Efficient gene expression from integration-deficient lentiviral vectors in the spinal cord. Gene Ther 20 (2013), 645–657.
32. 32 Saenz, DT, Barraza, R, Loewen, N, Teo, W, Poeschla, EM, Feline immunodeficiency virus-based lentiviral vectors. Cold Spring Harb Protoc 2012 (2012), 71–76.
33. 33 Vargas, J Jr, Gusella, GL, Najfeld, V, Klotman, ME, Cara, A, Novel integrase-defective lentiviral episomal vectors for gene transfer. Hum Gene Ther 15 (2004), 361–372.
34. 34 Mátrai, J, Cantore, A, Bartholomae, CC, Annoni, A, Wang, W, Acosta-Sanchez, A, et al. Hepatocyte-targeted expression by integrase-defective lentiviral vectors induces antigen-specific tolerance in mice with low genotoxic risk. Hepatology 53 (2011), 1696–1707.
35. 35 Yáñez-Muñoz, RJ, Balaggan, KS, MacNeil, A, Howe, SJ, Schmidt, M, Smith, AJ, et al. Effective gene therapy with nonintegrating lentiviral vectors. Nat Med 12 (2006), 348–353.
36. 36 Suwanmanee, T, Hu, G, Gui, T, Bartholomae, CC, Kutschera, I, von Kalle, C, et al. Integration-deficient lentiviral vectors expressing codon-optimized R338L human FIX restore normal hemostasis in Hemophilia B mice. Mol Ther 22 (2014), 567–574.
37. 37 Berger, G, Goujon, C, Darlix, JL, Cimarelli, A, SIVMAC Vpx improves the transduction of dendritic cells with nonintegrative HIV-1-derived vectors. Gene Ther 16 (2009), 159–163.
38. 38 Coutant, F, Frenkiel, MP, Despres, P, Charneau, P, Protective antiviral immunity conferred by a nonintegrative lentiviral vector-based vaccine. PLoS One, 3, 2008, e3973.
39. 39 Dai, B, Yang, L, Yang, H, Hu, B, Baltimore, D, Wang, P, HIV-1 Gag-specific immunity induced by a lentivector-based vaccine directed to dendritic cells. Proc Natl Acad Sci USA 106 (2009), 20382–20387.
40. 40 Deng, Y, Guan, J, Wen, B, Zhu, N, Chen, H, Song, J, et al. Induction of broadly neutralising HCV antibodies in mice by integration-deficient lentiviral vector-based pseudotyped particles. PLoS One, 8, 2013, e62684.
41. 41 Hu, B, Dai, B, Wang, P, Vaccines delivered by integration-deficient lentiviral vectors targeting dendritic cells induces strong antigen-specific immunity. Vaccine 28 (2010), 6675–6683.
42. 42 Hu, B, Yang, H, Dai, B, Tai, A, Wang, P, Nonintegrating lentiviral vectors can effectively deliver ovalbumin antigen for induction of antitumor immunity. Hum Gene Ther 20 (2009), 1652–1664.
43. 43 Karwacz, K, Mukherjee, S, Apolonia, L, Blundell, MP, Bouma, G, Escors, D, et al. Nonintegrating lentivector vaccines stimulate prolonged T-cell and antibody responses and are effective in tumor therapy. J Virol 83 (2009), 3094–3103.
44. 44 Negri, DR, Bona, R, Michelini, Z, Leone, P, Macchia, I, Klotman, ME, et al. Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells. Hum Gene Ther 21 (2010), 1029–1035.
45. 45 Negri, DR, Michelini, Z, Baroncelli, S, Spada, M, Vendetti, S, Bona, R, et al. Nonintegrating Lentiviral Vector-Based Vaccine Efficiently Induces Functional and Persistent CD8+ T Cell Responses in Mice. J Biomed Biotechnol, 2010, 2010, 534501.
46. 46 Negri, DR, Michelini, Z, Baroncelli, S, Spada, M, Vendetti, S, Buffa, V, et al. Successful immunization with a single injection of non-integrating lentiviral vector. Mol Ther 15 (2007), 1716–1723.
47. 47 Coluccio, A, Miselli, F, Lombardo, A, Marconi, A, Malagoli Tagliazucchi, G, Gonçalves, MA, et al. Targeted gene addition in human epithelial stem cells by zinc-finger nuclease-mediated homologous recombination. Mol Ther 21 (2013), 1695–1704.
48. 48 Joglekar, AV, Hollis, RP, Kuftinec, G, Senadheera, S, Chan, R, Kohn, DB, Integrase-defective lentiviral vectors as a delivery platform for targeted modification of adenosine deaminase locus. Mol Ther 21 (2013), 1705–1717.
49. 49 Lombardo, A, Cesana, D, Genovese, P, Di Stefano, B, Provasi, E, Colombo, DF, et al. Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods 8 (2011), 861–869.
50. 50 Provasi, E, Genovese, P, Lombardo, A, Magnani, Z, Liu, PQ, Reik, A, et al. Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer. Nat Med 18 (2012), 807–815.
51. 51 Torikai, H, Reik, A, Liu, PQ, Zhou, Y, Zhang, L, Maiti, S, et al. A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR. Blood 119 (2012), 5697–5705.
52. 52 Yi, G, Choi, JG, Bharaj, P, Abraham, S, Dang, Y, Kafri, T, et al. CCR5 Gene Editing of Resting CD4(+) T Cells by Transient ZFN Expression From HIV Envelope Pseudotyped Nonintegrating Lentivirus Confers HIV-1 Resistance in Humanized Mice. Mol Ther Nucleic Acids, 3, 2014, e198.
53. 53 Miller, AD, Retrovirus packaging cells. Hum Gene Ther 1 (1990), 5–14.
54. 54 Pear, WS, Nolan, GP, Scott, ML, Baltimore, D, Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acad Sci USA 90 (1993), 8392–8396.
55. 55 Burns, JC, Friedmann, T, Driever, W, Burrascano, M, Yee, JK, Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc Natl Acad Sci USA 90 (1993), 8033–8037.
56. 56 Naldini, L, Blömer, U, Gallay, P, Ory, D, Mulligan, R, Gage, FH, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272 (1996), 263–267.
57. 57 Bryson, PD, Zhang, C, Lee, CL, Wang, P, A tetracycline-regulated cell line produces high-titer lentiviral vectors that specifically target dendritic cells. J Vis Exp, 76, 2013, 50606.
58. 58 Cockrell, AS, Ma, H, Fu, K, McCown, TJ, Kafri, T, A trans-lentiviral packaging cell line for high-titer conditional self-inactivating HIV-1 vectors. Mol Ther 14 (2006), 276–284.
59. 59 Ikeda, Y, Takeuchi, Y, Martin, F, Cosset, FL, Mitrophanous, K, Collins, M, Continuous high-titer HIV-1 vector production. Nat Biotechnol 21 (2003), 569–572.
60. 60 Kafri, T, van Praag, H, Ouyang, L, Gage, FH, Verma, IM, A packaging cell line for lentivirus vectors. J Virol 73 (1999), 576–584.
61. 61 Throm, RE, Ouma, AA, Zhou, S, Chandrasekaran, A, Lockey, T, Greene, M, et al. Efficient construction of producer cell lines for a SIN lentiviral vector for SCID-X1 gene therapy by concatemeric array transfection. Blood 113 (2009), 5104–5110.
62. 62 Xu, K, Ma, H, McCown, TJ, Verma, IM, Kafri, T, Generation of a stable cell line producing high-titer self-inactivating lentiviral vectors. Mol Ther 3 (2001), 97–104.
63. 63 Kaplan, AH, Swanstrom, R, The HIV-1 gag precursor is processed via two pathways: implications for cytotoxicity. Biomed Biochim Acta 50 (1991), 647–653.
64. 64 Planelles, V, Bachelerie, F, Jowett, JB, Haislip, A, Xie, Y, Banooni, P, et al. Fate of the human immunodeficiency virus type 1 provirus in infected cells: a role for vpr. J Virol 69 (1995), 5883–5889.
65. 65 Rogel, ME, Wu, LI, Emerman, M, The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection. J Virol 69 (1995), 882–888.
66. 66 Gossen, M, Bujard, H, Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89 (1992), 5547–5551.
67. 67 Hwang, LH, Gilboa, E, Expression of genes introduced into cells by retroviral infection is more efficient than that of genes introduced into cells by DNA transfection. J Virol 50 (1984), 417–424.
68. 68 Persons, DA, Mehaffey, MG, Kaleko, M, Nienhuis, AW, Vanin, EF, An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene. Blood Cells Mol Dis 24 (1998), 167–182.
69. 69 Cockrell, AS, van Praag, H, Santistevan, N, Ma, H, Kafri, T, The HIV-1 Rev/RRE system is required for HIV-1 5’ UTR cis elements to augment encapsidation of heterologous RNA into HIV-1 viral particles. Retrovirology, 8, 2011, 51.